Clinical Trial Detail

NCT ID NCT02966730
Title Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

follicular lymphoma

Therapies

Ibrutinib

Age Groups: senior adult

No variant requirements are available.